For individuals considering either compound, understanding the biochemical differences, clinical evidence, and personal biomarker context becomes essential before provider consultation
Circulating amylin signals through the amylin family of receptors which are comprised of two subunits, the shared G-protein calcitonin receptor (CALCR) and one of three receptor activity-modifying protein subunits (RAMPs 1-3) to generate AMY1R, AMY2R and AMY3R, respectively
Tirzepatide (Mounjaro, Zepbound) Strengths: Highest efficacy for both glucose control and weight loss Dual mechanism (GLP-1 + GIP) may provide unique benefits Once-weekly dosing Generally well-tolerated Considerations: Higher cost than semaglutide Less long-term safety data (newer medication) Cardiovascular outcome trial not yet complete (though expected to be positive) Best for: Patients prioritizing maximum weight loss
They are frequently debilitating and significantly impact a person's quality of life
Injectable GLP-1 medications like Semaglutide have shown the highest average weight loss percentages in clinical research
Together, they create a smart burn stack: OxyShred Non-Stim targets fat oxidation
